First, current CDx should modulate their pipelines and integrate a deeper analysis of LRs, which have recently been shown to be an important part of BRCA1/2 alterations, leading to false negatives if tests are focused on tumor samples [17,114]. This evidence concerns the gene BRCA1 and neoplasm.